Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
|
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [1] Discovery of Novel BRD4 Ligand Scaffolds by Automated Navigation of the Fragment Chemical Space
    Piticchio, Serena G.
    Martinez-Cartro, Miriam
    Scaffidi, Salvatore
    Rachman, Moira
    Rodriguez-Arevalo, Sergio
    Sanchez-Arfelis, Ainoa
    Escolano, Carmen
    Picaud, Sarah
    Krojer, Tobias
    Filippakopoulos, Panagis
    von Delft, Frank
    Galdeano, Carles
    Barril, Xavier
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (24) : 17887 - 17900
  • [2] Drug Discovery of Acetophenone Derivatives as BRD4 Inhibitors
    Zhang, Zhimin
    Huang, Wenhai
    Zheng, Xiaoliang
    Li, Chuansheng
    Shen, Zhengrong
    LETTERS IN DRUG DESIGN & DISCOVERY, 2020, 17 (03) : 323 - 329
  • [3] Parallel approaches to the discovery of novel BRD4 inhibitors
    Jones, David H.
    de Groot, Marcel J.
    Heald, Robert
    Arhin, Ebenezer
    Goodwin, Ria
    Burton, Brenda
    Kulagowski, Jan
    Brown, David
    Irving, Steven
    Bazin, Richard
    Bruce, Deborah
    Devos, Rene
    Price, Steven
    Ray, Nick
    Lockey, Peter
    Montana, John
    Albertella, Mark R.
    Green, Simon R.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Binding Kinetics versus Affinities in BRD4 Inhibition
    Kuang, Ming
    Zhou, Jingwei
    Wang, Laiyou
    Liu, Zhihong
    Guo, Jiao
    Wu, Ruibo
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2015, 55 (09) : 1926 - 1935
  • [5] Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain
    Heinzelmann, Germano
    Henriksen, Niel M.
    Gilson, Michael K.
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2017, 13 (07) : 3260 - 3275
  • [6] Interplay of condensation and chromatin binding underlies BRD4 targeting
    Strom, Amy R.
    Eeftens, Jorine M.
    Polyachenko, Yury
    Weaver, Claire J.
    Watanabe, Hans -Frederick
    Bracha, Dan
    Orlovsky, Natalia D.
    Jumper, Chanelle C.
    Jacobs, William M.
    Brangwynne, Clifford P.
    MOLECULAR BIOLOGY OF THE CELL, 2024, 35 (06)
  • [7] Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
    Chen, Jingjing
    Li, Yalei
    Zhang, Jie
    Zhang, Minmin
    Wei, Aihuan
    Liu, Hongchun
    Xie, Zhicheng
    Ren, Wenming
    Duan, Wenwen
    Zhang, Zhuo
    Shen, Aijun
    Hu, Youhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 209
  • [8] Discovery and lead identification of quinazoline-based BRD4 inhibitors
    Yang, Shyh-Ming
    Urban, Daniel J.
    Yoshioka, Makoto
    Strovel, Jeffrey W.
    Fletcher, Steven
    Wang, Amy Q.
    Xu, Xin
    Shah, Pranav
    Hu, Xin
    Hall, Matthew D.
    Jadhav, Ajit
    Maloney, David J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (21) : 3483 - 3488
  • [9] Discovery and characterization of a novel small molecule BRD4 protein degrader
    Dragovich, Peter
    Blake, Robert
    Chen, Hai
    Chen, Jinhua
    Cosino, Ely
    Enquist, Ida
    Gascoigne, Karen
    Hartman, Steven
    Kaufman, Susan
    Kirkpatrick, Donald
    Kleinheinz, Tracy
    Li, Chun Sing
    Lu, Ying
    Murray, Jeremy
    Pillow, Thomas
    del Rosario, Geoff
    Rose, Christopher
    Rowntree, Rebecca
    Staben, Leanna
    Staben, Steven
    Wai, John
    Wertz, Ingrid
    Wilson, Catherine
    Xu, Zijin
    Xue, Juanjuan
    Yao, Hui
    Yu, Shang-Fan
    Wei, Binqing
    Wong, Mengling
    Zhang, Chenghong
    Zhang, Donglu
    Zhou, Hao
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [10] Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
    Zhangxu He
    Haomiao Jiao
    Qi An
    Xin Zhang
    Dan Zengyangzong
    Jiale Xu
    Hongmin Liu
    Liying Ma
    Wen Zhao
    Acta Pharmaceutica Sinica B, 2022, 12 (01) : 291 - 307